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Acute hemolysis by hydroxycloroquine was observed in G6PD-deficient patient with severe
COVD-19 related lung injury






The coronavirus disease COVID19 is a global health pandemic
emergency. The disease, named coronavirus disease 2019 (COVID-19)
by the WHO, presents symptoms that range from mild to severe and
fatal respiratory conditions. As the epidemy emerged and spread ra-
pidly worldwide, more than 400,000 confirmed cases of COVID-19 and
around 20,000 related deaths have been reported globally [1]. Clinical
presentation might range from mild to severe lower respiratory tract
symptoms, resulting in life-threatening complication such as acute re-
spiratory distress syndrome (ARDS). Up to now, two serious cor-
onavirus-related outbreaks occurred in the past two decades: severe
acute respiratory syndrome (SARS) in 2003 and Middle East respiratory
syndrome (MERS) in 2012 [2]. Since SARS-CoV-2 has shown analogous
mechanisms to SARS, existing antiviral drugs used in the past epidemies
- such as ribavirin, interferon, lopinavir-ritonavir - were primarily
proposed. Drugs repositioning lists several benefits: the drugs are al-
ready available on the market and therefore promptly accessible and
their safety profile and dosage are already known. Based on promising
preliminary data against a wide range of viruses, chloroquine sulfate
(CQ) – a drug used for a long time for the prophylaxis of malaria - was
recommended at the dosage of 500 mg BID for the treatment of SARS-
CoV-2. The other choice was hydroxychloroquine (HCQ) sulfate. First
synthesized in 1946 as the hydroxyl derivative of CQ, HCQ has shown a
less toxic profile than CQ in animal models and, more crucially, it is
available worldwide since it has been used to treat autoimmune dis-
eases such as rheumatoid arthritis and systemic lupus erythematosus
[3–5]. Since the two molecules share similar structures and im-
munomodulating functions, HCQ was also recommended and included
in the therapeutic armamentarium to treat the infection of SARS-CoV-2,
at the dosage of 200 mg BID [6]. Thus, the protease inhibitor combi-
nation lopinavir/ritonavir – already approved for the treatment of the
human immunodeficiency virus (HIV) type 1 – in association with ei-
ther CQ or HCQ represents the standard of care for COVID-19 symp-
tomatic patients so far [6,7].
Caution in prescribing CQ/HCQ treatment in patients with glucose-
6-phosphate dehydrogenase (G6PD) deficiency is generally observed
due to the pro-hemolytic effect of these molecules [3–5]. Glucose-6-
phosphate dehydrogenase (G6PD) deficiency is the most common
worldwide distributed hereditary red cells enzymatic defect, with a
prevalence of 400 million affected subjects [8,9]. Although G6PD
deficiency is a benign haematologic disorder, acute haemolytic crisis
triggered by exposition to oxidative agents such as fava beans, drugs or
infections might be its most common life-threatening clinical pre-
sentation.
A 72-year-old caucasian man was admitted to ED for fatigue, dys-
pnea, dizziness and fever. No significant elements were present in pa-
tient's history, in particular no neurologic disorders, haemolytic anemia
nor recent introduction of new drugs. He was suffering of ischemic
cardiomyopathy with recent stenting of the interventricular coronary
artery. Physical examination revealed significant reduction of periph-
eral saturation in ambient air (87%), and the chest X-Ray documented
the presence of bilateral interstitial pneumonia. Laboratory tests
showed normal hemoglobin (Hb: 15 g/dL) and mild reduction of pla-
telet count as observed in COVD19 affected patients [10]. The presence
of COVID19 infection was documented by RT-PCR analysis of the nose-
throat swab. The patient was hospitalized in the COVID19 Unit and
treatment with lopinavir plus HCQ and oxygen support was stared. At
48 hours after hospitalization, we observed an acute drop in Hb
(Figure 1a) associated with the appearance of hemoglobinuria. No
change in leukocyte count was observed, while reactive protein C was
increased. Renal tests were normal. LDH levels were undetermined due
to the intravascular haemolysis (Fig. 1A). Both direct and indirect an-
tiglobulin tests were negative, excluding an immune-mediated acute
haemolysis. The peripheral blood smears showed (i) anisopoikilocy-
tosis; reticulocytes as large and round-shaped cells; (ii) some “hemi-
ghost” cells characterized by packed hemoglobin from one side and
large vacuum cytoplasm; (iii) microspherocytes; (iv) schistocytes (2-
3%), suggesting a blistering process (Figure 1b). HCQ was withdrawn
and the patient was transfused. The trigger of acute haemolytic crisis
was HCQ in a patient with suspected G6PD deficiency affected by
COVID19 lung disease.
Our patient might be affected by Mediterannean variant of G6PD
deficiency, which is more sensitive to pro-oxidant drugs compared to
African G6PD A variant. No conclusive data are available on the pos-
sible pro-hemolytic impact of CQ/HCQ on patient with G6PD deficiency
[3–5]. In COVID-19 emergency we believe it is important to warning
the possible hemolytic effects of CQ/HCQ in patients with G6PD defi-
ciency. Thus, the acute drop in Hb levels in the early days of CQ/HCQ
treatment of COVID19 symptomatic patient should be considered
https://doi.org/10.1016/j.ejim.2020.04.020
Received 30 March 2020; Accepted 6 April 2020
European Journal of Internal Medicine 77 (2020) 136–137
Available online 20 April 2020
0953-6205/ © 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
T
suspicious for possible G6PD deficiency. CQ/HCQ should be dis-
continued and the hemolysis is generally self-limiting when the CQ/
HCQ is withdrawn.
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Figure 1. (a) The graph shows lab exams. RBCs: red blood cells. (b) Upper and lower panels. Peripheral blood smears. Acute haemolysis induced by hydroxy-
chloroquine is characterized by marked anisopoikilocytosis with erythrocytes of different shapes and sizes, hemi-ghost blister cells and microspherocytes.
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